Table 3 Biochemical parameters
|  | Standard of care (N = 31) | Alirocumab (N = 30) | P Value |
|---|---|---|---|
LDL cholesterol, mmol/L | |||
 Baseline | 3.18 ± 0.97 | 3.04 ± 0.78 | – |
 After 36 weeks treatment | 2.22 ± 0.69 | 1.32 ± 0.39 | < 0.0001 |
 Changes from baseline | −0.96 ± 0.59 | −1.72 ± 0.51 | < 0.0001 |
HDL cholesterol, mmol/L | |||
 Baseline | 1.30 ± 0.41 | 1.41 ± 0.61 | – |
 After 36 weeks treatment | 1.38 ± 0.43 | 1.48 ± 0.47 | 0.35 |
 Changes from baseline | 0.08 ± 0.36 | 0.07 ± 0.38 | 0.74 |
Triglycerides, mmol/L | |||
 Baseline | 1.56 (1.19 to 2.38) | 1.84 (1.19 to 2.56) | – |
 After 36 weeks treatment | 1.53 (1.09 to 2.26) | 1.54 (1.00 to 2.09) | 0.68 |
 Changes from baseline | −0.05 (0.64 to 1.42) | −0.29 (− 0.96 to 0.35) | 0.077 |
CRP, mg/L | |||
 Baseline | 1.62 (0.90 to 3.00) | 1.69 (0.75 to 3.37) | – |
 After 36 weeks treatment | 1.10 (0.89 to 2.50) | 1.59 (0.92 to 2.61) | 0.64 |
 Changes from baseline | 0.54 (−0.46 to 1.34) | 0.12 (−0.74 to 1.08) | 0.50 |